



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/B

Applicant(s): Yoshinaga et al.

Serial No.: 09/728,420

Group Art Unit No.: 1644

Filed: November 28, 2000

Examiner: Roark, Jessica H.

For: Novel Polypeptides Involved in Immune Response

Docket No.: A-579C

RECEIVED

MAY 24 2002

RESPONSE AND AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

This is in response to the Office Action dated February 19, 2002 in which the specification was objected to and Claims 1-42 were subject to a restriction requirement.

Please amend the application as follows:

In the specification:

At page 10, replace the last paragraph with the following:

Figure 1. A) (SEQ ID NOS: 1 & 2) DNA and amino acid sequence murine CRP1 (mCRP1).

Predicted signal sequence of CRP1 is underlined at the amino-terminus and the experimentally determined pro-peptide cleavage site is indicated by an asterisk. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) (SEQ ID NOS: 3, 4 & 5) ...

At page 11, replace the second paragraph with the following:

Figure 2. A) (SEQ ID NOS: 6 & 7) DNA and amino acid sequence of murine B7RP1 (mB7RP1).

Predicted signal sequence of B7RP1 is underlined at the amino-terminus and the experimentally determined pro-peptide cleavage site is indicated by an asterisk. Predicted transmembrane sequence is underlined toward the carboxy-terminus. B) (SEQ ID NOS: 8, 9 & 10) Amino acid alignment of B7RP1 protein sequence (mB7RP1) with murine CD80 (mCD80).

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360694002US

Date of Deposit: May 17, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 39 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Lynne Buchsbaum
Printed NameLynne Buchsbaum
Signature